Evidence map›Paper›PMID 36656836›Full record

ArticlePLoS pathogens2023

SERINC5: One antiviral factor to bind them all.

Uddhav Timilsina, Spyridon Stavrou

Abstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Uddhav TimilsinaDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, United States of America.
Spyridon StavrouDepartment of Microbiology and Immunology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, United States of America.ORCID 0000-0002-3962-8917

Funding

Elucidating the role of SERINC5 in SARS-CoV-2 infectionR21AI160950 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI STAVROU, SPYRIDON · 2022 to 2023
$439k
The role of SERINC5 during retrovirus infection in vivoR21AI144147 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI STAVROU, SPYRIDON · 2020 to 2021
$436k
NIAID NIH HHS R21 AI144147NIAID NIH HHS R21 AI160950
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

HIV-1HIV InfectionsAntiviral AgentsHumansMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusAntiviral AgentsMembrane Proteinsnef Gene Products, Human Immunodeficiency VirusSERINC5 protein, human

Identifiers

PMID36656836
PMCPMC9851522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.